Human Growth Hormone Market Size, Share, and Trends 2026 to 2035

Revenue, 2025

USD 8.10 Bn

Forecast Year, 2035

USD 25.79 Bn

CAGR, 2026 - 2035

12.28%

Report Coverage

Global

What is the Human Growth Hormone Market Size?

The global human growth hormone market size is calculated at USD 8.10 billion in 2025 and is predicted to increase from USD 9.11 billion in 2026 to approximately USD 25.79 billion by 2035, expanding at a CAGR of 12.28% from 2026 to 2035.

Human Growth Hormone Market Key Takeaways

• North America will generate the maximum market share between 2026 and 2035.
• The growth hormone deficiency application segment contributed the maximum market share in 2025.
• The hospital pharmacy distribution channel segment had a significant market share in 2025.

Strategic Overview of the Global Human Growth Hormone Industry

The pituitary gland produces human growth hormone which induces growth in adults and in children and this is a peptide hormone which does the work of regeneration, reproduction, repair and cell metabolism. This hormone primarily engages in regulating growth. Fat metabolism and body fluid regulation is other functions of human growth hormones. They also help in the growth of muscles and bones. Fat accumulation is caused due to the deficiency of this hormone. It also leads to various diseases which may cause short bowel syndrome, muscle wasting, acromegaly and gigantism. The prevalence of chromosomal disease which is Turner's disease or Turner syndrome, is due to the deficiency of growth hormones. Increasing awareness among the consumers about the health benefits associated with the consumption of human growth hormone drugs is expected to drive the market in the long run. It also aids in the improvement of muscular strength and performance.

The COVID-19 epidemic is expected to have an effect on the worldwide human growth hormone market. According to a Frontiers article, patients with low growth hormone production are at risk for COVID-19, which requires attention to aid in COVID-19 prevention. Patients suffering from Prader-Willi syndrome must also take precautions. Turner syndrome patients are at an increased risk of serious disease from the COVID-19 virus.

A growth hormone deficiency occurs in humans when the pituitary gland does not have an appropriate concentration of human growth hormone. This deficiency is addressed by injecting human growth hormone subcutaneously. Growth hormone deficiency can also be caused by genetic illnesses such as Prader-Willi syndrome and Turner syndrome, resulting in delayed puberty and lower height than usual.

Artificial Intelligence: The Next Growth Catalyst in Human Growth Hormone

Artificial Intelligence is fundamentally impacting the human growth hormone (HGH) industry by enabling a shift towards personalized medicine and improving treatment efficacy through data-driven approaches. AI algorithms analyze vast amounts of patient data, including genetic information, to detect HGH deficiencies earlier and more accurately, which informs tailored treatment plans and optimizes dosing for individual needs.

Indrug discovery, AI accelerates the identification and development of new and improved HGH formulations, such as long-acting therapies, by predicting drug efficacy and safety profiles faster than traditional methods.

Human Growth Hormone Market Growth Factors

A growth hormone shortage develops in humans when the pituitary gland does not produce enough human growth hormone. Human growth hormone is subcutaneously injected to treat this deficit. Genetic diseases such as Prader-Willi syndrome and Turner syndrome can also induce growth hormone deficit, resulting in delayed puberty and shorter height than typical.

Furthermore, several firms are investing in R&D to create a growth hormone with fewer side effects and that will be a long-term therapy. The expansion of the market can be associated with the increasing cases of disorders caused by the deficiency of this hormone. Constant efforts made by governments and other private groups to raise awareness of growth hormone deficiency and high productivity. Other reasons such as enhanced treatment awareness, and growing g cases of numerous health conditions like the neuropsychiatric conditions will create more demand for Human Growth Hormone drugs and favour market growth. The quick development of new human growth hormone molecules is projected to fuel the growth of the human growth hormone market.

The public's knowledge of the usage of synthetic growth hormone treatment has gradually improved over time. However, increased industry research into the causes of growth abnormalities, as well as an increase in diagnosis, has resulted in increased market growth. Among these conditions are paediatric growth hormone insufficiency, idiopathic short height, adult growth hormone deficiency, and inherited disorders such as Turner syndrome and Prader-Willi syndrome. One in every 3800 children worldwide has a growth hormone deficiency. Turner syndrome affects around one in every 2000 females, while Prader-Willi syndrome affects approximately one in every 30,000 people.

Market Outlook

• Market Growth Overview: The human growth hormone market is expected to grow significantly between 2026 and 2035, driven by high adoption of advanced delivery systems, shift to long-acting formulations, and expansion of online and retail pharmacies.
• Sustainability Trends:Sustainability trends involve green chemistry and eco-friendly manufacturing, waste reduction and responsible disposal, and sustainable packaging and the circular economy.
• Major Investors: Major investors in the market include Novo Nordisk A/S, Pfizer Inc., Eli Lilly and Company, Merck KGaA, Roche, and Ipsen Pharma.
• Startup Economy:The startup economy is focused on disruptive innovation in two key areas: improving the formulation and delivery of the hormone to enhance patient quality of life, and developing digital health solutions to monitor adherence and optimize treatment outcomes.

Market Scope

MarketDynamics

Key Market Drivers

Steady Growth in Industries

• Human growth hormone is essential for human development. In humans, growth hormone (GH) shortage occurs when the pituitary gland does not produce enough HGH. In humans, this deficit is addressed by subcutaneous injections of recombinant human growth hormone. Human growth hormone insufficiency can also be caused by genetic illnesses such as Prader-Willi syndrome and Turner syndrome, resulting in delayed puberty and shorter-than-average height.

Increasing R and D initiatives

• The market for human growth hormones is likely to be driven by a robust product pipeline and substantial R&D initiatives for the development of innovative growth hormone treatments. In 2018, Novo Nordisk was engaged in Phase II clinical trial results for Somapacitan, an experimental GH medication recommended for the treatment of juvenile growth hormone insufficiency. Furthermore, Ascendis Pharma A/S announced Phase III clinical trial findings for their TransCon hGH, intended for juvenile growth hormone insufficiency, in May 2019.

Key Market Challenges

Adverse effects of synthetic growth hormones

• However, the adverse effects of synthetic growth hormones, such as muscular soreness, joint pain, and fluid retention, as well as the high cost of therapies utilising artificial growth hormones, are impeding market expansion. Furthermore, strict government clearances are projected to limit industry growth and development in the approaching years. On the contrary, rising disposable income and increased healthcare spending in developing nations are expected to generate attractive possibilities for growth hormone manufacturers in the future.
• The high cost of hGH treatments, as well as the severe undesirable effects associated with hGH, may stymie market growth throughout the projection period. For example, UPMC Children's Hospital of Pittsburgh reports that possible side effects of this hormone are joint pains, knee pain and hip pain. It may also cause allergies like swelling, rash, hives and also an increase in the levels of blood sugar.

Key Market Opportunities

The growing number of hospital pharmacies will provide considerable market expansion potential

• The growth hormone business is divided into three distribution channels: online medstores, retail pharmacies, and hospital pharmacies. The hospital pharmacy segment is estimated to account for around 55% of the market in 2025, and it is expected to grow at a moderate rate over the forecast period. As the prevalence of diagnosis of growth disorders in hospitals grows, so does the need for growth hormone therapy in hospital pharmacies.

Segment Insights

Application Insights

The GH deficiency category had the biggest market share in 2025 and is likely to maintain its dominance throughout the forecast period. This is due to increased awareness regarding the early detection and treatment of GH insufficiency in people, as well as the introduction of innovative medications into the hGH market. For example, Ascendis Pharma A/S gained Orphan Designation from the European Commission (EC) in October 2018 for its experimental long-acting GH medication for humans, TransCon hGH, which is recommended for the treatment of paediatric GH deficiency.

Similarly, Ferring Pharmaceuticals Inc. got USFDA clearance in January 2018 for its novel recombinant HGH, Zomacton (somatropin), which is approved for the treatment of adults with GH insufficiency. The GH deficiency sector is further subdivided into adult GH deficiency and paediatric GH deficiency, with the latter expected to dominate the market throughout the projection period due to a rising number of pipeline medications. For example, in October 2019, Pfizer Inc. and its partner OPKO Health Inc. stated that their Phase III research of Somatrogon in pre-pubertal children with hGH fulfilled its primary goal of non-inferiority to daily somatropin.

Turner's syndrome accounted for the second-largest market share in2025 and is expected to emerge as a profitable category during the projected period. This might be linked to increased efforts by different public and private groups to raise awareness about Turner syndrome early diagnosis and treatment. Every year in February, non-profit groups such as Turner Syndrome Support Society (UK), Turner Syndrome Society of the United States, and Turner Syndrome Foundation observe "Turner Syndrome Awareness Month"; and undertake a worldwide campaign to raise awareness of the illness.

Distribution Channel Insights

The human growth hormone market has been classified into hospital pharmacy, retail pharmacy, internet pharmacy, and specialty pharmacy. In2025, the hospital pharmacy category had a sizable market share. This large percentage can be ascribed to an increase in hospital visits as people become more aware of GH insufficiency and its treatment. According to the Children's Hospital of Philadelphia (CHOP), prescriptions for growth hormone have climbed from 5.1 patients per 10,000 enrollees in 2001 to 14.6 patients per 10,000 in 2016.

Because of the increasing prevalence of pharmacies in developed nations such as North America and Europe, the online pharmacy segment is likely to grow at a considerable CAGR over the forecast period. Furthermore, the growing popularity of online pharmacies in emerging markets such as India and China is likely to propel category expansion in the future years.

Regional Insights

U.S. Human Growth Hormone Market Size and Growth 2026 to 2035

The U.S. human growth hormone market size is exhibited at USD 2.44 billion in 2025 and is projected to be worth around USD 7.94 billion by 2035, growing at a CAGR of 12.52% from 2026 to 2035.

North America is expected to account for the highest sharedue to variables such as favorable reimbursement scenarios, established healthcare infrastructure, considerable government initiatives, and expanding healthcare awareness. Furthermore, increasing access to innovative pharmaceuticals as a result of the presence of important firms in the region benefits the North American market. Pfizer, Inc., Eli Lilly and Company, and Genentech, Inc. are three significant players located in the United States that provide a diverse variety of human GH medicines in the region.

U.S. Human Growth Hormone Market Trend

In the U.S. market, is significantly shifting towards long-acting, once-weekly formulations and user-friendly injector pens to improve patient compliance and convenience. This trend, along with the rising awareness and diagnosis of adult growth hormone deficiency, is accelerating market growth.

Over the projection period, Asia Pacific is expected to grow at a rapid pace.Key competitors are focusing on attaining a significant market share in prospective Asia Pacific nations such as Japan and China through product approval and launch. For example, in March 2017, Novo Nordisk A/S, a Danish pharmaceutical firm, began a phase III clinical study in Japan for their HGH somapacitan, which is designed for the treatment of adult growth hormone insufficiency.

China Human Growth Hormone Market Trend

China's market is experiencing robust growth driven by high awareness of growth disorders and a large patient base. Domestic suppliers, particularly GenSci, dominate the market with strong government support and favorable regulations. The market is transitioning to long-acting formulations and online distribution channels, indicating a future with increased competition, improved patient convenience, and potentially lower prices.

Technological advancements in China and the growing disposable income will play a significant role in the growth of the Asia Pacific market. Advancements in the research and development to an increased consumption of human growth hormones in Japan. Many investments are made by the government in various nations of the Asia Pacific region and this is expected to fuel the market growth in the long run. Prevalence of genetic diseases in the Asia Pacific region will have a significant impact on the growth of this market. Short term treatment for various disorders with the help of human growth hormone in the European nations will support this market. Government expenses made on treating such diseases will have a positive impact on the market growth. Germany is the leading market of human growth hormone in the European region.

How did Europe gain a notable share in the Human Growth Hormone Market?

Europe's robust, state-funded healthcare systems and favorable reimbursement policies facilitate early diagnosis and widespread patient access. The region benefits from major domestic pharmaceutical companies like Novo Nordisk A/S that invest heavily in R&D and advanced, user-friendly delivery systems like injector pens. Europe has also been a pioneer in developing and adopting cost-effective HGH biosimilars.

Germany Human Growth Hormone Market Trends

Germany's market is driven by an advanced healthcare system, comprehensive insurance coverage, and early integration of innovative therapies. The market is increasingly driven by the availability of long-acting, once-weekly formulations like SKYTROFA and Sogroya, which enhance patient adherence and convenience. This trend is complemented by a high adoption of biosimilars that increase access and the growing popularity of online pharmacies as a discrete and efficient distribution channel for patients.

Value Chain Analysis of the Human Growth Hormone Market

Research & Development and Drug Discovery (R&D): This foundational stage involves genetic research, protein synthesis, clinical trials, and developing novel HGH formulations, including long-acting variants.

• Key Players:Pfizer Inc., Eli Lilly and Company, Novo Nordisk A/S, Genentech (Roche), Ascendis Pharma

Manufacturing and Production (Operations/Inbound Logistics): This stage focuses on the large-scale, high-quality manufacturing of the active pharmaceutical ingredients (APIs) and the final drug product in sterile facilities.

• Key Players: Novo Nordisk, Pfizer, and Sandoz International GmbH.

Sales, Marketing & Distribution (Outbound Logistics/Marketing & Sales): This stage involves promoting HGH products to endocrinologists, pediatricians, hospitals, and pharmacies, and managing the cold chain logistics required for temperature-sensitive HGH products.

• Key Players: McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Genentech, and Ipsen Pharma.

Prescription and Patient Access (Service): Healthcare providers, primarily endocrinologists and pediatricians, diagnose GHD and prescribe the appropriate HGH therapy.

• Key Players: hospitals, clinics, private physician practices, and the NHS.

Pharmacy Distribution and Patient Support (Service): The final stage involves the dispensing of HGH medication to the patient through hospital, retail, or online pharmacies and providing ongoing support, adherence monitoring, and patient education.

• Key Players: Walgreens, CVS Caremark

Top Companies in the Human Growth Hormone Market & Their Offerings

• Novo Nordisk: A Danish pharmaceutical giant, Novo Nordisk is a dominant player in the HGH market with its leading product Norditropin and the once-weekly Sogroya.
• Merck & Co.: Merck & Co., known globally as MSD outside of the U.S. and Canada, contributes to the HGH market with its product Saizen (somatropin) and associated electronic delivery devices like the easy-to-use cool.Click the autoinjector. The company focuses on global distribution and is involved in R&D for next-generation HGH therapies and related growth hormone treatments.
• Eli Lilly & Company:Eli Lilly is a major American pharmaceutical company that participates in the HGH market with Humatrope (somatropin), a well-established brand for treating various growth disorders. They also offer advanced delivery systems, including a range of injector pens designed for convenience and dosing accuracy to enhance the patient experience.
• Pfizer Inc.: Pfizer is a significant player offering the product Genotropin (somatropin) and recently gained FDA approval for Ngenla, a once-weekly long-acting HGH treatment. Their contribution includes extensive global reach, R&D in long-acting formulations, and advanced delivery pen devices that cater to a broad patient population.
• Teva Pharmaceutical Industries:Teva is a global leader in generic and specialty medicines and is involved in the HGH market by providing its own branded biosimilar HGH product, Tevagrastim/Lonquex, in various markets. Their focus is on increasing accessibility to HGH treatment through cost-effective biosimilar options and a wide distribution network.
• Novartis AG:Novartis, through its Sandoz subsidiary, is a key contributor to the European and global biosimilar HGH market with its product Omnitrope (somatropin). Their presence helps drive market competition, reduce costs, and expand patient access to high-quality HGH therapy through a robust biosimilar portfolio.
• Anhui Anke Biotechnology (Group) Co., Ltd: This Chinese company is a major domestic player in the HGH market in China, offering both daily and developing long-acting somatropin products.
• Roche: Roche, through its subsidiary Genentech, is a major contributor to the HGH market with Nutropin and Nutropin AQ (somatropin) treatments. The company leverages its strong R&D capabilities in biotechnology to produce high-quality human growth hormone therapies and explore new related treatments.
• Ipsen:Ipsen is a global specialty pharmaceutical company that offers the HGH product Nutropin in some markets and focuses on R&D for targeted treatments in endocrinology.

Recent Developments in the Human Growth Hormone Industry

• In May 2025, Sandoz introduced a new OMNITROPE formulation for the Egyptian market, which is already approved by the FDA and EMA. This indicates ongoing efforts to tailor formulations and ensure access in different regions. (Source: dailynewsegypt.com)
• In May 2025, Novo Nordisk presented positive data from the Phase III REAL8 study, showing that once-weekly Sogroya was non-inferior (at least as effective) to once-daily Norditropin. This showcases improving growth rates for children with various growth disorders, supporting its push for expanded indications. (Source: appliedclinicaltrialsonline.com)
• February 2021: The Pfizer and OPKO Health Inc. announced that the European Medicines Agency has authorised Somatrogon for the treatment of individuals lacking in juvenile growth hormone. Pfizer and OPKO have been working together to develop and market Somatrogon for GHD therapy since 2014.

Segments Covered in the Report

By Application

• Growth Hormone Deficiency
• Prader-Willi Syndrome
• Turner Syndrome
• Small For Gestational Age
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa